Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura

Blood Transfusion

Volumn 6, Issue 3, 2008, Pages 127-135

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ADAMTS13; Thrombotic thrombocytopenic purpura; TTP

Indexed keywords

NEUTRALIZING ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; PLASMA; PROGNOSIS; RECURRENCE RISK; REVIEW; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 47749132284     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0056-07     Document Type: Review

References (46)

1. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-81.
2. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2004; p. 407-23.
3. Mannucci PM, Lavoretano S, Peyvandi S. The thrombotic microangiopathies. Blood Transf 2005; 3: 120-35.
4. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-4.
5. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-59.
6. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
7. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
8. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
9. Tsai HM, Lian EC. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
10. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
11. Tsai HM. Molecular mechanisms in thrombotic thrombovytopenic purpura. Semin Thromb Hemost 2004; 30: 549-56.
12. Schulman I, Pierce M, Lukens A, et al. Studies on thrombopoeisis. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16: 943-57.
13. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298: 1350-2.
14. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
15. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-9.
16. Scheiflinger F, Knöbl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241-3.
17. Rieger M, Mannucci PM, Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-7.
18. van der Plas RM, Schiphorst ME, Huizinga EG, et al. Von Willebrand factor proteolysis is deficient in classic but not in bone marrow transplantation- associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-802.
19. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-36.
20. Furlan M, Lammle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2002; 28: 167-72.
21. Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol 2004; 41: 41-7.
22. Shelat S, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005; 31: 659-72.
23. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a fluorogenic substrate for ADAMTS13 assay. Br J Haemost 2005; 129: 93-100.
24. Groot E, Hulstein JJ, Rison CN, et al. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 698-9.
25. Miyata T, Kokame K, Banno F. Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol 2005; 12: 384-9.
26. Studt JD, Bohm M, Budde U, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-7.
27. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9.
28. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-40.
29. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
30. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-80.
31. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
32. Coppo P, Bengoufa D, Veyradier A, et al; Reseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83: 233-44.
33. Peyvandi F, Ferrari S, Lavoretano S, et al. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433-9.
34. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9.
35. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
36. Hovinga JA, Studt JD, Alberio L, et al. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41: 75-82.
37. Mal H, Veyradier A, Brugiere O, et al. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation 2006; 81: 1628-32.
38. Blot E, Decaudin D, Veyradier A, et al. Cancer-related thrombotic microangiopathy secondary to von Willebrand factor-cleaving protease deficiency. Thromb Res 2002; 106: 127-30.
39. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-31.
40. Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44: 146-50.
41. Coppo P, Wolf M, Veyradier A, et al; Reseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2005; 132: 66-74.
42. Böhm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-52.
43. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000; 65: 251-5.
44. Willis MS, Bandarenko N. Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Semin Thromb Hemost 2005; 31: 700-8.
45. Ferrari S, Scheiflinger F, Rieger M, et al; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-22.
46. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 2: 232-9.